Public affairs is Pfizer focus

NEW YORK: In the wake of a CEO change, Pfizer is renaming its corporate affairs practice as public affairs to better reflect the increasing importance of influencing public policy and opinion to the company's success.

NEW YORK: In the wake of a CEO change, Pfizer is renaming its corporate affairs practice as public affairs to better reflect the increasing importance of influencing public policy and opinion to the company's success.

The change is part of a larger reorganization of Pfizer's management structure that aims to make it more "agile and entrepreneurial." Pfizer's new CEO, Jeff Kindler, previously had been head of legal and corporate affairs at the company.

While the "newly named division essentially will stay the same in terms of its construction," noted Paul Fitzhenry, Pfizer's senior director of corporate media relations, Kindler's elevation to CEO from head of corporate affairs exemplified the shift.

In a memo sent to Pfizer employees, Kindler explained that the company must learn to make decisions faster because, among other things, "patients and their families are using newly available information to take more control over their healthcare decisions."

As part of the change, Rich Bagger will head Pfizer's new worldwide public affairs and policy division, which previously had been called the corporate affairs division.

Formerly Pfizer's SVP of government relations, Bagger will now oversee public policy development, government relations, communications, media, philanthropy, and stakeholder advocacy for the company.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in